Please assess the completion status of the following clinical trial:

Trial Title: Golimumab Plus UVB-311nm in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients with psoriatic arthritis who receive treatment with golimumab~* Patient wish for treatment of psoriatic skin lesions~Exclusion Criteria:~* Pregnancy or lactation~* Presence and/or history of malignant melanoma~* Presence and/or history of invasive squamous cell carcinoma of the skin~* Presence and/or history of more than 3 basal cell carcinomas~* Dysplastic nevus syndrome~* Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)~* Autoimmune disorders such as lupus erythematosus or dermatomyositis~* Abnormal photosensitivity and photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others~* General poor health status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).